The adequate management of cardiovascular diseases remains one of the major challenges
of modern medicine. Nanomaterials may offer new and unique treatment opportunities that …

Gene-based therapy represents the latest advancement in medical biotechnology. The
principle behind this innovative approach is to introduce genetic material into specific cells …

Neutralizing antibody (NAb) activity against the viral capsid of adeno-associated viral (AAV)
vectors decreases transduction efficiency, thus limiting transgene expression. Several …

Abstract Purpose of Review The current knowledge of pathophysiological and molecular
mechanisms responsible for the genesis and development of heart failure (HF) is absolutely …

Induced pluripotent stem cells (iPSCs) originate from the reprogramming of adult somatic
cells using four Yamanaka transcription factors. Since their discovery, the stem cell (SC) field …

Despite advances in treatment over the past decade, heart failure remains a significant
public health burden and a leading cause of death in the developed world. Gene therapy …

Phosphorylation of serines, threonines, and tyrosines is a central event in signal
transduction cascades in eukaryotic cells. The phosphorylation state of any particular protein …

MicroRNAs (miRNAs) have become potential targets for the treatment of heart failure (HF). It
has been shown that miR-1 can reverse cardiac hypertrophy during the compensatory …

Gene delivery tools based on adeno-associated viruses (AAVs) are a popular choice for the
delivery of transgenes to the central nervous system (CNS), including gene therapy …

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, progressive in nature, and
known to have a negative impact on mortality, morbidity, and quality of life. Patients requiring …